BioNTech SE is a global next-generation immunotherapy company focused on developing novel medicines for cancer, infectious diseases, and other serious conditions. The company leverages the immune system's power to address diseases with unmet medical needs and significant global health burdens. BioNTech primarily sells mRNA vaccines, protein-based therapeutics, cell therapies, and small molecules.
- COVID-19 Vaccine Revenues - Generates revenue from the sale of COVID-19 vaccines, which is the major contributor to the company's revenue.
- Share of Collaboration Partners' Gross Profit - Receives a share of the gross profit from collaboration partners, primarily Pfizer, based on sales in their territories.
- Direct Product Sales to Customers - Supplies the COVID-19 vaccine directly in territories like Germany and Türkiye.
- Sales to Collaboration Partners - Manufactures and sells products to collaboration partners.
- Research & Development Revenues from Collaborations - Earns revenue from R&D collaborations.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Prof. Ugur Sahin, M.D. ExecutiveBoard | CEO and Co-Founder | None | CEO and Co-Founder of BioNTech, actively involved in strategic and operational development, particularly in oncology and COVID-19 vaccine efforts. | View Report → |
Jens Holstein Executive | Chief Financial Officer (CFO) | Non-executive board member at Veracyte Inc. | Joined BioNTech in 2021; previously CFO at MorphoSys AG and held multiple CFO/general management roles at Fresenius SE Group. | |
Ryan Richardson Executive | Chief Strategy Officer (CSO) | None | Joined BioNTech in 2018; previously worked in healthcare investment banking at J.P. Morgan and as a health economist at IMS Health. | |
Sean Marett Executive | Chief Business Officer (CBO) and Chief Commercial Officer (CCO) | Chairman of PHMR Ltd; Supervisory board member at AiCuris AG | Joined BioNTech in 2012; led commercialization of the Pfizer-BioNTech COVID-19 vaccine and negotiated key financing rounds and supply agreements. | |
Sierk Poetting, Ph.D. Executive | Chief Operating Officer (COO) | None | Joined BioNTech in 2014; previously held leadership roles at Novartis and worked as a consultant at McKinsey & Company. | |
Baroness Nicola Blackwood Board | Supervisory Board Member | Chair of Oxford University Innovation; Chair of Genomics England; Managing Director of Blackwood Intelligence Limited; Member of the House of Lords | Appointed to the Supervisory Board in 2023; brings expertise in science and innovation; holds leadership roles in prominent UK organizations. | |
Helmut Jeggle Board | Chair of the Supervisory Board | Managing Partner at Salvia GmbH; Supervisory board member at 4SC AG, Tonies SE, AiCuris AG, AFFiRiS AG, APK AG | Chair of BioNTech's Supervisory Board since 2008; instrumental in guiding the company’s strategic direction; previously held roles at Hexal AG and ATHOS KG. | |
Michael Motschmann Board | Supervisory Board Member | Co-founder and Management Board member at MIG Capital AG; Supervisory board member at APK AG, HMW Emissionshaus AG, Affiris AG; Advisory board member at Efficient Energy GmbH, Temedica GmbH, AMSilk GmbH | Supervisory Board member since 2008; co-founder of MIG Capital AG and active in venture capital investments. |
-
Although you have significant ongoing Phase II and III trials, could you elaborate on how you plan to balance the increasing R&D expenses with cost control measures, especially as you invest in assets like BNT327?
-
With regards to your updated guidance at the low end of the range due to low demand and pricing in low and middle income countries, how do you plan to mitigate these challenges and ensure revenue growth in the face of reduced COVID-19 vaccine demand?
-
Given the approximately EUR 600 million accrued for contractual disputes with licensees and collaborators this year, can you provide more clarity on the nature of these disputes and how they might impact future financials?
-
Considering the missed endpoints in the Phase III flu COVID combo program and competitors like Moderna expecting to launch their combo next year, how are you adjusting your strategy to remain competitive in the combination vaccine market?
-
As you expect to maintain or gain market share in key markets this year for your COVID-19 vaccine and believe in improved visibility into vaccine demand, how confident are you in your ability to sustain this given potential shifts in vaccination rates and market dynamics?
Research analysts who have asked questions during BioNTech earnings calls.
Cory Kasimov
Evercore ISI
4 questions for BNTX
Daina Graybosch
Leerink Partners
4 questions for BNTX
Jessica Fye
JPMorgan Chase & Co.
4 questions for BNTX
Tazeen Ahmad
Bank of America
4 questions for BNTX
Terence Flynn
Morgan Stanley
4 questions for BNTX
Yaron Werber
TD Cowen
4 questions for BNTX
Akash Tewari
Jefferies
3 questions for BNTX
Asthika Goonewardene
Truist Securities
2 questions for BNTX
Harry Gillis
Berenberg
2 questions for BNTX
Mohit Bansal
Wells Fargo & Company
2 questions for BNTX
Asad Haider
Goldman Sachs
1 question for BNTX
Chris Shibutani
Goldman Sachs Group, Inc.
1 question for BNTX
Eliana Merle
UBS
1 question for BNTX
Evan Seigerman
BMO Capital Markets
1 question for BNTX
Jay Olson
Oppenheimer & Co. Inc.
1 question for BNTX
John Newman
Canaccord Genuity Group Inc.
1 question for BNTX
Manos Mastorakis
Deutsche Bank
1 question for BNTX
Nishan Sarna
Citigroup
1 question for BNTX
Simon Baker
Redburn Atlantic
1 question for BNTX
Suzanne van Voorthuizen
Kempen & Co
1 question for BNTX
Yifeng Liu
HSBC
1 question for BNTX
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Biotheus | 2025 | BioNTech’s acquisition of Biotheus was aimed at strengthening its oncology portfolio with the BNT327 pan-tumor platform; the deal’s total value was $800 million in cash (plus a small portion in ADS) with up to $150 million in performance-based payments, providing full global rights to BNT327, access to an in-house antibody generation platform, and a new R&D hub and manufacturing facility as an indirect Chinese subsidiary. |
InstaDeep | 2023 | BioNTech’s acquisition of InstaDeep involved buying 100% of the remaining shares for approximately €500 million, structured with cash, BioNTech shares, and milestone-based payments, to integrate AI/ML capabilities across industries while InstaDeep continues as a UK-based global subsidiary. |
Medigene | 2022 | In 2022, BioNTech collaborated with and acquired key assets from Medigene, including its next-generation preclinical TCR program (PRAME TCR) and licenses to the PD1-41BB switch receptor, for an upfront payment of EUR 26 million plus milestone, regulatory, and commercial payments, thereby securing exclusive worldwide rights to further TCR immunotherapies. |
Recent press releases and 8-K filings for BNTX.
- BioNTech reported Q3 2025 total revenues of EUR 1,519 million, an increase from EUR 1,245 million in Q3 2024, largely due to $700 million recognized from the BMS collaboration. The company recorded a net loss of EUR 29 million for the quarter.
- For the full-year 2025, BioNTech increased its revenue guidance to EUR 2.6 billion-EUR 2.8 billion while lowering R&D expense guidance to EUR 2 billion-EUR 2.2 billion, reflecting active portfolio management and efficiencies. The company still expects a loss for the 2025 financial year.
- In its oncology pipeline, pumitamig advanced enrollment in two global registration trials in lung cancer and is on track to initiate a TNBC phase III in 2025. The BLA submission for trastuzumab-pamirtecan (TPEM) is now planned for 2026, a delay from the original end of 2025, due to ongoing discussions with the FDA.
- BioNTech reported total revenues of EUR 1,519 million for Q3 2025, an increase from EUR 1,245 million in Q3 2024, largely due to the recognition of $700 million from the BMS collaboration.
- The company posted a net loss of EUR 29 million and a basic and diluted loss per share of EUR 0.12 for Q3 2025, contrasting with a net income of EUR 198 million and EPS of EUR 0.82 in the comparative prior year period.
- BioNTech updated its full-year 2025 financial guidance, raising revenue expectations to EUR 2.6 billion-EUR 2.8 billion while lowering R&D expenses to EUR 2 billion-EUR 2.2 billion, SG&A expenses to EUR 550 million-EUR 650 million, and capital expenditures to EUR 200 million-EUR 250 million. The company anticipates reporting a loss for the 2025 financial year.
- The Biologics License Application (BLA) submission for trastuzumab-pamirtekan (TPEM, BNT323) is now planned for 2026, a delay from the original target of end of 2025, attributed to ongoing discussions with the FDA for additional data requirements.
- In Q3 2025, BioNTech made significant clinical progress with pomitamic (BNT327), advancing enrollment in two global lung cancer registration trials and remaining on track to initiate a TNDC phase 3 trial this year, with potential first launches before the end of the decade.
- BioNTech reported Q3 2025 revenues of EUR 1,519 million, an increase from EUR 1,245 million in Q3 2024, primarily driven by $700 million from the BMS collaboration. The company recorded a net loss of EUR 29 million and a basic and diluted loss per share of EUR 0.12 for the quarter.
- The company increased its full-year 2025 revenue guidance to EUR 2.6 billion-EUR 2.8 billion (from EUR 1.7 billion-EUR 2.2 billion), mainly due to the recognition of the $700 million from the BMS collaboration.
- BioNTech also lowered its full-year 2025 R&D expense guidance by EUR 600 million to a new range of EUR 2 billion-EUR 2.2 billion, and SG&A expense guidance by EUR 100 million to EUR 550 million-EUR 650 million. The company expects to report a loss for the 2025 financial year.
- The BLA submission for trastuzumab-pamirtekan (TPEM) is now planned for 2026, a delay from the previously guided end of 2025, due to ongoing discussions with the FDA.
- Progress continues on key oncology programs, including pomitamic, with enrollment advancing in two global registration trials in lung cancer and a phase 3 initiation in TNBC on track for this year, targeting first potential launches before the end of the decade.
- BioNTech SE has raised its full-year 2025 revenue forecast to between €2.6 billion and €2.8 billion, primarily due to a $700 million payment from its partnership with Bristol-Myers Squibb (BMS).
- The company's third-quarter revenue grew 22% to €1.52 billion, partly driven by progress in its oncology portfolio, including positive interim data for the bispecific antibody candidate pumitamig in lung cancer trials.
- BioNTech is strategically shifting its focus from declining COVID-19 vaccine revenues to cancer therapies, planning additional pivotal trials for pumitamig in colorectal and gastric cancers in 2026.
- Concurrently, BioNTech lowered its expense guidance for 2025, with research and development expenses now projected between €1.8 billion and €2.2 billion.
- BioNTech reported revenues of €1,519 million for Q3 2025, an increase from €1,245 million in Q3 2024. The company recorded a net loss of €29 million and basic earnings per share of (€0.12) for Q3 2025.
- As of September 30, 2025, BioNTech maintained a strong balance sheet with approximately €16.7 billion in total cash and cash equivalents plus security investments.
- The company increased its full-year 2025 revenue guidance to €2,600 – €2,800 million and reduced its expenditures guidance for R&D, SG&A, and capital expenditure.
- BioNTech made significant progress in its oncology pipeline, advancing Pumitamig with registrational Phase 3 trials in lung and breast cancer, progressing late-stage trials for mRNA cancer immunotherapies (FixVac and iNeST), and advancing Trastuzumab pamirtecan towards BLA submission.
- Regulatory approvals were received for the variant-adapted COVID-19 vaccine, COMIRNATY, in the U.S., Europe, UK, and Japan.
- BioNTech SE reported total revenues of €1,518.9 million for the three months ended September 30, 2025, and a net loss of €28.7 million for the period. For the nine months ended September 30, 2025, total revenues were €1,962.5 million, resulting in a net loss of €831.1 million and basic loss per share of €3.45.
- COVID-19 vaccine revenues decreased by 23% to €853.3 million in Q3 2025 compared to Q3 2024, while revenues from out-licensing increased by €613.0 million due to an upfront payment from a global strategic partnership with Bristol-Myers Squibb Company.
- As of September 30, 2025, the company maintained a strong liquidity position with cash and cash equivalents of €10,092.9 million. Subsequent to the reporting period, BioNTech commenced a public exchange offer for all outstanding shares of CureVac N.V., implying an aggregate equity value of approximately $1.25 billion.
- BioNTech reported Q3 2025 revenues of €1.5 billion, a net loss of €28.7 million, and a basic and diluted loss per share of €0.12.
- The company's financial position was strengthened to €16.7 billion in cash, cash equivalents, and security investments as of September 30, 2025, partly due to a $1.5 billion payment from its Bristol Myers Squibb partnership.
- BioNTech increased its full-year 2025 revenue guidance to €2.6-2.8 billion and lowered expense guidance ranges for R&D, SG&A, and capital expenditures.
- The company launched its variant-adapted COVID-19 vaccine for the 2025/2026 vaccination season and reported encouraging interim Phase 2 data for its bispecific antibody candidate pumitamig (BNT327/BMS986545), with plans for additional pivotal trials.
- BioNTech SE and Pfizer Inc. announced on August 27, 2025, that the U.S. Food and Drug Administration (FDA) has approved their LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1).
- The vaccine is approved for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
- Shipping of the LP.8.1-adapted vaccine will begin immediately, with availability in U.S. pharmacies, hospitals, and clinics in the coming days.
- The global mRNA Platform market is projected to decline from an estimated US$152.0 Billion in 2024 to US$129.1 Billion by 2030, representing a CAGR of -2.7%.
- This overall market trend is influenced by a projected decline in the COVID-19 Vaccine segment, which is expected to reach US$102.1 Billion by 2030 with a -6.3% CAGR.
- Conversely, the Cancer Vaccine segment is anticipated to grow significantly at an 86.1% CAGR over the analysis period.
- The U.S. market holds a leading position, valued at $64.5 Billion in 2024, with China forecasted to reach $13.8 Billion by 2030.
- Key drivers for the mRNA platform include increasing infectious diseases, technological advancements, and substantial investments in biotechnology research, supported by regulatory processes.
- The global vaccines market is projected to grow from $76.05 billion in 2024 to $118.85 billion by 2030, representing a Compound Annual Growth Rate of 7.72%.
- Technological innovations, such as messenger RNA platforms and synthetic biology, are revolutionizing vaccine development, allowing for rapid cycle designs and flexible formulations.
- U.S. tariff changes in 2025 are increasing raw material costs, necessitating new supply chain strategies and pushing manufacturers towards regional production hubs.
- Regional dynamics vary, with the Americas leveraging robust infrastructures, Europe and Africa facing mixed distribution capacities, and Asia-Pacific emerging as a manufacturing hub.